Procter & Gamble Hygiene and Health Care (500459) Q1 24/25 earnings summary

Executive summary

• Unaudited financial results for the quarter ended September 30, 2024, were approved and released following a Board meeting on October 30, 2024.

• Financial statements have been reviewed by the Audit Committee and subjected to a limited review by statutory auditors.

Financial highlights

• Revenue from operations for Q2 FY25 was ₹113,506 lakhs, up from ₹93,906 lakhs in Q2 FY24 and ₹113,273 lakhs in Q1 FY25.

• Profit before tax for Q2 FY25 stood at ₹28,537 lakhs, compared to ₹28,447 lakhs in Q2 FY24 and ₹11,228 lakhs in Q1 FY25.

• Net profit for Q2 FY25 was ₹21,190 lakhs, up from ₹21,069 lakhs in Q2 FY24 and ₹3,122 lakhs in Q1 FY25.

• Basic and diluted EPS for Q2 FY25 was ₹65.28, compared to ₹64.91 in Q2 FY24 and ₹24.97 in Q1 FY25.

Key financial ratios and metrics

• Gross margin improved year-over-year, with total expenses at ₹85,829 lakhs in Q2 FY25 versus ₹86,965 lakhs in Q2 FY24.

• Employee benefits expense for Q2 FY25 was ₹6,051 lakhs, down from ₹6,372 lakhs in Q2 FY24.